Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01673711 · ClinicalTrials.gov registry record
Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer
A clinical trial of Lung Cancer and Tobacco Use Disorder, sponsored by University of Minnesota.
- Completed
- Registry status
- 350
- Enrollment target
- 3
- Study locations
NCT01673711 is a study of Lung Cancer and Tobacco Use Disorder that has completed, run by University of Minnesota. The registered enrollment target is 350 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (63% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01673711, a study of Lung Cancer and Tobacco Use Disorder, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 350 participants
- Enrollment target
- 3
- Study locations
Study Summary
This clinical trial studies deuterated phenanthrene tetraol in smokers who are at high risk for lung cancer. Studying samples of urine in the laboratory from smokers who are at high risk for lung cancer may help doctors learn more about biomarkers related to cancer.
Conditions Studied
Interventions
- DRUG deuterated phenanthrene tetraol
- DRUG pharmacological study
- DRUG laboratory biomarker analysis
Study Locations (3)
Minnesota
- Mayo Clinic - Rochester
New York
- Roswell Park Cancer Institute - Buffalo
British Columbia
- BC Cancer Agency - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2012-07 |
| Est. Completion | 2019-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01673711
The ClinicalTrials.gov registry entry for NCT01673711 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (63% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which deuterated phenanthrene tetraol is the first listed.
NCT01673711 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Minnesota, New York, British Columbia.
Frequently Asked Questions
What is clinical trial NCT01673711 about?
NCT01673711 is a clinical study titled "Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer". This clinical trial studies deuterated phenanthrene tetraol in smokers who are at high risk for lung cancer. Studying samples of urine in the laboratory from smokers who are at high risk for lung cancer may help doctors learn more about biomarkers related to cancer.
What is the current status of trial NCT01673711?
This trial is currently completed. The enrollment target is 350 participants. The study started on 2012-07. Estimated completion is 2019-09-30.
What conditions does trial NCT01673711 study?
This clinical trial studies the following conditions: Lung Cancer, Tobacco Use Disorder, Squamous Lung Dysplasia.
What interventions are being tested in trial NCT01673711?
The interventions under investigation include: deuterated phenanthrene tetraol (DRUG), pharmacological study (DRUG), laboratory biomarker analysis (DRUG).
Who is sponsoring clinical trial NCT01673711?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01673711 being conducted?
This trial has 3 study locations across Minnesota, New York, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.